Objective To investigate the association between nirmatrelvir plus ritonavir (NMV-r) and the
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …

Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …

Background The effects of nirmatrelvir/ritonavir (NMV/r [Paxlovid]) on coronavirus disease
2019 (COVID-19) outcomes in younger vaccinated adults are unclear. The objective of this …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Background Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …

Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. VV116 is
an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. We conducted an …

Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

We read with interest the retrospective observational study investigating the short-term effect
of oral anti-viral agents on United States Veterans aged 65 years and older who were at …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

The Omicron variant of SARS-CoV-2 is a new variant of concern after Alpha, Beta, Gamma
and Delta variants. The amino acid mutations in the viral antigens, especially in the receptor …